Q-omics provides the consensus-scored TPP2 profile across patient tissues and cancer cell-line models. TPP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPP2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TPP2 RNA expression shows 21,181 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TPP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPP2 survival associations across molecular data types. TPP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPP2 RNA expression–survival associations across cancer types. High TPP2 expression shows unfavorable associations in ACC, HNSC and UVM, but favorable associations in KIRC, BRCA and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPP2 RNA expression.
This table summarizes TPP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TPP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPP2 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, KIRP, BLCA and STAD. The KIRC box plot shows higher TPP2 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with TPP2 in patient tissues and cancer cell lines. In patient samples, TPP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
